文献速递慢阻肺

布地奈德/格隆溴铵/福莫特罗三联疗法对比双联疗法治疗慢阻肺的3期随机对照试验(KRONOS)

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2018-09-16

KRONOS为双盲、平行组、多中心3期随机对照试验,纳入1902例40-80岁、有吸烟史且症状性中重度至极重度慢阻肺患者,比较布地奈德/格隆溴铵/福莫特罗(BGF)计量吸入器与相应双联疗法。结果显示BGF显著改善FEV1 AUC0-4及晨间 trough FEV1,耐受性良好,肺炎发生率低。

要点

  • BGF较BFF及BUD/FORM显著改善FEV1 AUC0-4,差异分别为104 mL和91 mL。
  • BGF较GFF显著改善晨间 trough FEV1(22 mL),对BUD/FORM非劣效。
  • BGF耐受性良好,肺炎发生率低(<2%),最常见不良事件为上呼吸道感染和鼻咽炎。

核心结论

  • BGF计量吸入器对症状性中重度至极重度慢阻肺患者有效且耐受良好,可能比相应双联疗法更合适,无论有无急性加重史。

研究设计与样本

  • 双盲、平行组、多中心3期随机对照试验,在加拿大、中国、日本和美国215个中心筛选3047例,随机1902例。
  • 纳入40-80岁、吸烟史≥10包年、确诊慢阻肺且接受≥2种吸入维持治疗至少6周仍有症状的患者。

主要发现

  • 最常见治疗中出现的不良事件为鼻咽炎(BGF 8%、GFF 7%、BFF 8%、BUD/FORM 9%)和上呼吸道感染(BGF 10%、GFF 6%、BFF 6%、BUD/FORM 7%)。
  • 肺炎发生率低(<2%)且各组相似;治疗相关死亡2例,均在GFF组。

关键数值与推荐

  • 主要终点:24周FEV1 AUC0-4(BGF vs BFF、BGF vs BUD/FORM)和晨间给药前 trough FEV1变化(BGF vs GFF、BFF vs BUD/FORM非劣效界值-50 mL)。
  • 非劣效界值:BFF vs BUD/FORM DPI的95%CI下限不低于-50 mL。

临床怎么用

  • 对于接受两种及以上吸入维持治疗仍有症状的中重度至极重度慢阻肺患者,BGF三联疗法可显著改善肺功能,且不依赖急性加重史。
  • BGF耐受性良好,肺炎发生率低,可作为相应双联疗法的替代选择。

局限性

  • 与BUD/FORM DPI的比较仅按欧洲/加拿大统计分析方式,非全球分析。
  • 研究未要求患者有急性加重史,结论外推至频繁急性加重人群需谨慎。
  • 治疗相关死亡2例均在GFF组,需进一步评估安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inhaled corticosteroids have been used in patients with chronic obstructive pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not well known. We aimed to compare the efficacy of a triple therapy with corresponding dual therapies in symptomatic patients with moderate to very severe COPD, without a requirement for a history of exacerbations. METHODS: In this double-blind, parallel-group, multicentre phase 3 randomised controlled trial, we recruited patients from hospitals and care centres in Canada, China, Japan, and the USA. Eligible patients were 40-80 years of age, were current or former smokers (with a smoking history of ≥10 pack-years), had an established clinical history of COPD, and were symptomatic for COPD, despite receiving two or more inhaled maintenance therapies for at least 6 weeks before screening. We randomly assigned patients (2:2:1:1) using an interactive web response system to receive budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler 320/18/9·6 μg (BGF MDI), glycopyrrolate/ formoterol fumarate metered-dose inhaler 18/9·6 μg (GFF MDI), budesonide/formoterol fumarate metered-dose inhaler 320/9·6 μg (BFF MDI), or open-label budesonide/formoterol fumarate dry-powder inhaler 400/12 μg (BUD/ FORM DPI). Primary endpoints for the Europe/Canada statistical analysis approach were FEV1 area under the curve from 0-4 h (AUC0-4) for BGF MDI versus BFF MDI and BGF MDI versus BUD/FORM DPI over 24 weeks; and change from baseline in morning pre-dose trough FEV1 for BGF MDI versus GFF MDI and non-inferiority of BFF MDI versus BUD/FORM DPI (margin of -50 mL from lower bound of 95% CI) over 24 weeks. Comparisons with BUD/FORM DPI were made for the Europe/Canada statistical analysis approach only. This study is registered with ClinicalTrials.gov, number NCT02497001. FINDINGS: Between Aug 20, 2015, and Jan 5, 2018, 3047 patients were screened from 215 sites, and 1902 were randomly assigned to receive BGF MDI (n=640), GFF MDI (n=627), BFF MDI (n=316), or BUD/FORM DPI (n=319). Over 24 weeks, BGF MDI significantly improved FEV1 AUC0-4 versus BFF MDI (least squares mean difference 104 mL, 95% CI 77 to 131; p<0·0001) and BUD/FORM DPI (91 mL, 64 to 117; p<0·0001). BGF MDI also significantly improved pre-dose trough FEV1 versus GFF MDI (22 mL, 4 to 39; p=0·0139) and was non-inferior to BUD/FORM DPI (-10 mL, -36 to 16; p=0·4390). At week 24, patients in the BGF MDI group had a significantly improved FEV1 AUC0-4 compared with patients receiving BFF MDI (116 mL, 95% CI 80 to 152; p<0·0001); there was a non-significant improvement in the change from baseline in morning pre-dose trough FEV1 at week 24 versus GFF MDI (13 mL, -9 to 36 mL; p=0·2375). The most common treatment-emergent adverse events were nasopharyngitis (n=49 [8%] in the BGF MDI group; n=41 [7%] in the GFF MDI group; n=26 [8%] in the BFF MDI group; and n=30 [9%] in the BUD/FORM DPI group) and upper respiratory tract infection (n=65 [10%]; n=38 [6%]; n=18 [6%]; and n=22 [7%]). Pneumonia incidence was low (<2%) and similar across treatments. There were two treatment-related deaths, both in the GFF MDI group. INTERPRETATION: BGF MDI was efficacious, well tolerated, and could be a more appropriate treatment than the corresponding dual therapies for symptomatic patients with moderate to very severe COPD, irrespective of exacerbation history. FUNDING: Pearl-a member of the AstraZeneca Group.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018. PMID: 30232048. doi:10.1016/S2213-2600(18)30327-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。